Christopher A. Scannell

Aug 2, 2024 | jamanetwork.com | Christopher A. Scannell |John A. Romley |Rebecca Myerson |Dana P. Goldman

Introduction Semaglutide was first approved under the brand name Ozempic (Novo Nordisk) as a weekly injection by the US Food and Drug Administration (FDA) in 2017 and is a first-line treatment for patients with type 2 diabetes at high cardiovascular risk.1 Alongside evidence of semaglutide’s cardiovascular and weight loss benefits,2 the FDA approved Rybelsus (Novo Nordisk), an oral formulation for the treatment of type 2 diabetes, in 2019, and Wegovy (Novo Nordisk), another injectable...